ยากลุ่ม Statin ในโรคหลอดเลือดสมอง Statin in Cerebrovascular Disease
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
ผลงานและสถิติ กลุ่มงานอายุรกรรม โรงพยาบาลมหาราชนครราชสีมา ประจำปีงบประมาณ 2544.
ผลงานและสถิติ กลุ่มงานอายุรกรรม โรงพยาบาลมหาราชนครราชสีมา ประจำปีงบประมาณ 2545.
ผลงานและสถิติ กลุ่มงานอาธุรกรรม โรงพยาบาลมหาราชนครราชสีมา ประจำปีงบประมาณ 2546.
Expert panel on prevention, detection, evaluation, and treatment of high blood cholesterol in adult. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).JAMA 2001;285:2486-97.
Blood pressure, Cholesterol, and Stroke in Eastem Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 352: 1801-7.
The West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med 19999; 341: 70-6.
The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pieffor MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with Pravastatin: The Cholesterol and Recurrent Event (CARE) Study. Circulation 1999; 99: 216-23.
The Long-term Intervention with Pravastatin Ischemic Disease Study (LIPIDS). N Engl J Med 199999:3339: 1349-57.
The Heart Protection Study Collaborative Group: a randomized placebo-controlled trial (HPS). Lancet 2002;
: 7-22 .
Sever PS, Dahlof'B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of conary and stroke events with atorvastatin in bypertensive patients who have average or lower-than-average cholesterol concencentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
Crouse JR 3 rd, Byinyton RP, Band MG, Espeland MA, Craven TE, Sprinkle JW, etal. Pravastatin, Lipid and Atherosclerosis in the Carotid arteries(PLAC-II) AmJ Cardiol 1995; 75: 455-9.
Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect lovastain on earty carotid atherosclerosis and cardiovascular events. AsymptomaticCarotid Antery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in famullial bypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357: 577-81.
Muir KW, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-5.
Ridker PM, Hennekens CH, Buring SE, Rifai N. C reactive protein and other markers of inflammation in prediction of cardiovascular discase in women. N Engl J Med 2000; 342: 836-43.
Ridker PM, Cushman M, Stempfer MJ, Tracy RP, Hennekens CH. Inflammation, Aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM. The Air Force/Texas coronary artherosclerotis prevention study itrvestigators. Measurement of C-reactive protein for the targeting of statin theory in the primary prevention of acute coronary event. N Engl J Med 2001; 344: 1959-65.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braumwald E. Long-term of C-reactive protein. The Cholesterol and Recurrent Event (CARE) investigators. Circulation 1999; 100: 230-5.
Albert MA, Danielson E, Rafai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.